Correlation of Quantitative Assay of HBsAg and HBV DNA Levels During Chronic HBV Treatment

[1]  V. Wong,et al.  Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  G. Nimmo,et al.  Detection of HBsAg mutants in a population with a low prevalence of hepatitis B virus infection , 2007, Journal of medical virology.

[3]  C. Galli,et al.  Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[4]  S. Bowden.  Serological and molecular diagnosis. , 2006, Seminars in liver disease.

[5]  L. Friedman,et al.  Serologic and molecular diagnosis of hepatitis B virus. , 2004, Infectious disease clinics of North America.

[6]  E. Magiorkinis,et al.  HBV virological assessment. , 2006, Journal of hepatology.

[7]  S. Nick,et al.  Evaluation of 17 CE‐marked HBsAg assays with respect to clinical sensitivity, analytical sensitivity, and hepatitis B virus mutant detection , 2006, Journal of medical virology.

[8]  A. Tamori,et al.  Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers , 2005, Journal of medical virology.

[9]  G. Gerken,et al.  Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial , 2005, The Lancet.

[10]  Sheng-Nan Lu,et al.  Correlation of quantitative assay of hepatitis B surface antigen and HBV DNA levels in asymptomatic hepatitis B virus carriers , 2004, European journal of gastroenterology & hepatology.

[11]  Yoshinori Iwatani,et al.  Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. , 2004, Journal of virological methods.

[12]  S. Locarnini,et al.  New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B , 2003, Hepatology.

[13]  R. D. de Man,et al.  Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase , 2003, Gut.

[14]  E. Schiff,et al.  Lamivudine as initial treatment for chronic hepatitis B in the United States. , 1999, The New England journal of medicine.

[15]  M. Beard,et al.  Research methodology. Part IV: Understanding canonical correlation analysis. , 1996, The ABNF journal : official journal of the Association of Black Nursing Faculty in Higher Education, Inc.

[16]  A. Detsky,et al.  Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B , 1993, Annals of Internal Medicine.

[17]  E. Schiff,et al.  A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B , 1990 .

[18]  E. Schiff,et al.  A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. , 1990, The New England journal of medicine.

[19]  W. Szmuness,et al.  A controlled clinical trial of the efficacy of the hepatitis B vaccine (heptavax B): A final report , 1981, Hepatology.